Intuitive Surgical shares fall as procedure growth slows despite Q2 earnings beat
Intuitive Surgical (ISRG) shares fell about 11% after Q2 results beat expectations but US procedure growth slowed. Revenue rose to $2.89B (vs $2.82B expected) and adjusted EPS was $2.80 (vs $2.51 expected). US procedure growth was 12% vs 14% in Q1. For 2026, da Vinci growth guidance stayed 13.5% to 15.5%, nearer the midpoint.
How this was made
The 30-second read
Why it matters
Near-term valuation pressure is driven by the gap between implied 2026 procedure growth (about 14.5%) and analyst expectations (~15.3%), alongside the US growth deceleration from 14% to 12% quarter over quarter.
Market read
This is a classic beat-but-miss on growth quality story, where guidance and US procedure trends dominate the tape.
What to watch
Tariff impact is quantified as about 1% on gross margin, and systems/instruments growth (systems revenue up, installed base rising) may support longer-term adoption even if near-term procedures are deferred.
Background
ISRG reported Q2 results that beat consensus, but investors focused on moderating US procedure growth tied to deferred treatments and insurance coverage changes after ACA premium subsidies expired.
Ticker impact
ISRG shares fell about 11% after Q2 beat, but US procedure growth slowed to 12% from 14% and full-year outlook was cautious.
Bearish bias for the next several sessions as investors reprice the US growth trajectory and the implied 2026 procedure growth rate.
The article attributes the selloff directly to slower US procedure growth and a full-year outlook that comes in below analysts' expectations (about 14.5% vs ~15.3%).
Market effects
Robotic surgery peers may face read-across risk if investors generalize the US procedure growth slowdown as demand softness.
US-focused procedure growth deceleration is the key driver, potentially weighing on US medtech sentiment more than ex-US.
Worldwide growth guidance held, but the market is trading the US mix and insurance-related deferrals.
Counterpoint
The company maintained worldwide da Vinci growth guidance and reaffirmed margins and expense growth, suggesting the slowdown could be temporary timing effects rather than structural demand loss.
Key entities
- companyIntuitive Surgical
Robotic surgery company whose Q2 beat was offset by slower US procedure growth and a cautious full-year outlook.
%252FIntuitive%252520Surgical%252520Inc%252520location%252520sign-by%252520Sundry%252520Photography%252520via%252520iStock.jpg&w=3840&q=75)
